Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced the appointment of ...
Collaboration to leverage CAMP4’s RAP Platform® to accelerate development of novel antisense oligonucleotides (ASOs) for neurodegenerative and ...
An announcement from GlaxoSmithKline ( ($GB:GSK) ) is now available. GSK announced the recent purchase of 235,000 of its ordinary shares, as part ...
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to GSK’227, now known as risvutatug rezetecan ...
Although development of a jab for the H5N1 strain of avian flu is well under way, other strains are receiving less attention ...
GSK’s Exdensur is approved by the US FDA as a twice-yearly add-on treatment for severe eosinophilic asthma in patients 12 and ...
US regulators have approved GSK’s Exdensur treatment for severe asthma with an eosinophilic phenotype, marking the first ...
Royalty Pharma is acquiring a low-single digit pre-existing royalty on worldwide net sales on each of Nuvalent’s neladalkib and zidesamtinib from an undisclosed third party for up to $315 million. The ...
TipRanks on MSN
GSK expands share buyback program with recent purchase
GlaxoSmithKline ( ($GB:GSK) ) just unveiled an update. GSK has announced the purchase of 230,000 of its own ordinary shares as part of its ongoing ...
Background In real-world chronic obstructive pulmonary disease (COPD) care, poor adherence often leads to treatment ...
Phase 3 studies point to sustained disease control in patients who remain symptomatic despite standard therapies.
Executives on a DealBook Summit task force panel said fear was not the way to build teams capable of navigating difficult ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback